Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licartin after resection of hepatocellular carcinoma
ChiCTR-IPR-17011206Phase 4Not yet recruiting
- Sponsor
- Fourth Medical Center of PLA General Hospital
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of licofelone in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fourth Medical Center of PLA General Hospital. Primary endpoints: Time to recurrence and Overall survival. Planned start May 2017; status: not yet recruiting.
02
Drugs
licofelone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IPR-17011206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011206.